Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ellenbarrie Industrial Gases Ltd (ELLEN.NS)
Kolkata, IN
Founded in 1973 and based in Kolkata, India, Ellenbarrie Industrial Gases Limited manufactures and distributes a wide array of industrial gases, serving both the Indian domestic market and international clients. The company's operations are divided into two main segments: the sale of gases and project engineering services. Its extensive product catalog features gases like oxygen, nitrogen, argon, helium, hydrogen, carbon dioxide, nitrous oxide, and acetylene, in addition to various specialty gases. These essential resources support diverse sectors such as steel manufacturing, pharmaceuticals, shipbuilding, fabrication, food processing, and healthcare. Beyond gas supply, Ellenbarrie offers comprehensive project engineering solutions, which involve the design, engineering, procurement, installation, and commissioning of significant gas production facilities. Furthermore, the company specializes in the provision and setup of medical gas pipeline systems. It also supplies healthcare institutions with critical medical equipment, including emergency and transport ventilators, central sterilization systems, lung function testing apparatus, and electrocardiograph (ECG) machines.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.73% | -8.54% | -1.16% | +11.92% | -33.59% | -22.63% | -50.73% | -50.73% | -50.73% | -50.73% | -50.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+9,250.4% ★ Q1'26: -7.7% (vs Q3'24)
-
EPS growth Chemicals: +11.7%+10,034.4% ★ Q1'26: -28.3% (vs Q3'24)
-
FCF margin FCF growth · Chemicals: +41.7%+26.8% Q1'26: +13.4% (vs Q3'24)
-
EBIT margin Chemicals: +7.1%+27.9% ★ Q1'26: +22.6% (vs Q3'24)
-
ROIC Chemicals: +3.4%+7.3% ★ Q1'26: +5.4% (vs Q3'24)
-
Share dilution Chemicals: +0.0%+5.8% Q1'26: +7.7% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.58× ★ Q1'26: 1.79× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
3.44B
3.40B – 3.48B
|
4.84B
4.48B – 5.20B
+40.6% YoY
|
6.14B
5.58B – 6.70B
+26.8% YoY
|
6.75B
6.18B – 7.31B
+9.9% YoY
|
| EBITDA |
1.20B
1.19B – 1.21B
|
1.69B
1.56B – 1.81B
+40.6% YoY
|
2.14B
1.94B – 2.33B
+26.8% YoY
|
2.35B
2.15B – 2.55B
+9.9% YoY
|
| EBIT |
976.14M
965.22M – 987.05M
|
1.37B
1.27B – 1.47B
+40.6% YoY
|
1.74B
1.58B – 1.90B
+26.8% YoY
|
1.91B
1.75B – 2.07B
+9.9% YoY
|
| Net Income |
1.08B
1.07B – 1.09B
|
1.46B
1.30B – 1.56B
+35.3% YoY
|
1.86B
1.59B – 2.04B
+27.3% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
664.42M
656.99M – 671.85M
|
934.33M
865.05M – 1.00B
+40.6% YoY
|
1.18B
1.08B – 1.29B
+26.8% YoY
|
1.30B
1.19B – 1.41B
+9.9% YoY
|
| EPS |
7.80
7.70 – 7.90
|
10.35
9.40 – 11.30
+32.7% YoY
|
13.10
11.50 – 14.70
+26.6% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Padam Kumar Agarwala | MD & Chairman | 6M | male |
| Varun Kumar Agarwal | Joint MD & Director | 6M | male |
| K. Srinivas Prasad | Chief Financial Officer | 4M | male |
| Aditya Keshri | Company Secretary & Compliance officer | 820.0K | male |
| Sanjay Basak | Vice President of Project & Engineering | — | male |
| Subir Sen | General Manager of Human Resources | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELLEN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
